Skip to main content
2024 Guide to Patient Support Services

Janssen Biotech

2024 PSS Guide

Janssen CarePath Savings Program

Janssen CarePath
Janssen Compass
Johnson & Johnson Patient Assistance Foundation

Janssen Biotech, through Janssen CarePath, offers 1 source for patient support services focused on access, affordability, and treatment support for patients who are prescribed a Janssen Biotech oncology medication (Table). The Janssen Compass program is for patients prescribed Darzalex, Darzalex Faspro, Erleada, Rybrevant, Talvey, or Tecvayli and is available at JanssenCompass.com. This program includes patient information about each medication, educational treatment support, financial assistance information, and tools to help patients keep up with their medication regimens.

Janssen CarePath

This program provides drug-specific reimbursement programs, patient assistance information, and resource services that facilitate patient access to Janssen oncology medications.

Patients may qualify for enrollment in Janssen CarePath Savings programs if they have private or commercial health insurance that will cover a portion of the cost of medication. Patients participating in federal- or state-funded programs are not eligible. Drug-specific assistance information and eligibility criteria are available by selecting the appropriate drug at Janssen CarePath or by calling 877-227-3728, Monday-Friday, 8 am to 8 pm ET. Enrolled patients will receive a drug-specific Janssen CarePath Savings Program Card. Your patients and their caregivers can enroll patients in the Janssen CarePath Savings Program for Balversa, Erleada, and Zytiga at Janssen CarePath Portal.

Balversa Janssen CarePath Savings Program

Eligible patients with private or commercial health insurance may receive savings on out-of-pocket costs for Balversa. Depending on the patient’s health insurance plan, savings may apply toward costs for copay, coinsurance, or deductible. Eligible patients pay $5 per fill, with a $25,000 maximum program benefit per calendar year. Terms expire at the end of each calendar year and may change.

Darzalex/Darzalex Faspro and Yondelis Janssen CarePath Savings Program

Eligible patients who have been prescribed Darzalex, Darzalex Faspro, or Yondelis may be able to save on their copay, deductible, and coinsurance costs for medication.

Eligible patients will pay no more than $5 per infusion of Yondelis or Darzalex or subcutaneous injection of Darzalex Faspro, up to a $20,000 annual benefit.

Erleada Janssen CarePath Savings Program

Eligible patients may pay only $0 per month for Erleada, with an annual benefit up to $15,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Tecvayli Janssen CarePath

Janssen CarePath can provide information about insurance coverage, reimbursement, affordability, and access to forms for patients who are prescribed Tecvayli.

Rybrevant and Tecvayli Janssen CarePath Savings Program

Eligible patients who have been prescribed Rybrevant or Tecvayli may be able to save on their out-of-pocket medication costs. Depending on the patient’s health insurance plan, savings may apply toward copay, coinsurance, or deductible. Eligible patients will pay $5 per infusion, with a $26,000 maximum program benefit per calendar year.

Zytiga Janssen CarePath Savings Program

Eligible patients who have been prescribed Zytiga may be able to save on their copay, coinsurance, or deductible costs. Eligible patients will pay $10 monthly for Zytiga, up to a $12,000 annual benefit per calendar year.

Janssen CarePath General Resources

Access support is available at Janssen CarePath, which offers links to information on several topics, including affordability options, support for patients using government-funded healthcare programs or patients without health coverage, and the “Know Your State Interactive Tool.” It also provides a link to the Johnson & Johnson Patient Assistance Foundation, an independent, nonprofit organization that helps patients without prescription insurance coverage and without adequate financial resources to obtain their medications.

Information about the Johnson & Johnson Patient Assistance Foundation, including medications available through the Foundation’s patient assistance program, is available at JJPAF.org. The program is drug specific, and qualifying patients may be eligible to receive free Janssen medications for up to 12 months.

Drug specific eligibility requirements are available at JJPAF.org.

To apply for aid from the Johnson & Johnson Patient Assistance Foundation, patients and physicians must complete the Patient Assistance Program Application form.

TABLE Janssen Biotech Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Balversa (erdafitinib) tablets
Indications
Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alteration, as determined by an FDA-approved test, that has progressed during or after ≥1 lines of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
Patient support programs


Drug
Darzalex Faspro (daratumumab and hyaluronidase-fihj)
Indications
Patient support programs

Drug
Erleada (apalutamide)
Indications
Treatment of metastatic castration-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer
Patient support programs

Drug
Rybrevant (amivantamab-vmjw)
Indications
Treatment of adult patients with locally advanced or metastatic non–small-cell lung cancer with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Patient support programs

Drug
Talvey (talquetamab-tgvs)
Indications
Treatment of adults with relapsed/refractory multiple myeloma who received ≥4 previous lines of therapy, including proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody
Patient support programs

Drug
Tecvayli (teclistamab-cqyv)
Indications
Treatment of adult patients with relapsed or refractory multiple myeloma who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Patient support programs

Drug
Yondelis (trabectedin)
Indications
Treament of unresectable or metastatic liposarcoma or leiomyosarcoma in patients who received a prior anthracycline-containing regimen
Patient support programs

Drug
Zytiga (abiraterone acetate) tablets
Indications
Treament of metastatic castration-resistant prostate cancer, in combination with prednisone; metastatic high-risk, castration-sensitive prostate cancer, in combination with prednisone
Patient support programs

Darzalex (daratumumab) Indications

Treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem-cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma after ≥1 previous therapies; in combination with bortezomib, melphalan, and prednisone in newly diagnosed patients ineligible for ASCT; in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received ≥1 prior therapies; in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received 1-3 lines of therapy; in combination with pomalidomide and dexamethasone after ≥2 previous therapies, including lenalidomide and a proteasome inhibitor (PI); as monotherapy in patients who have received ≥3 prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent

Darzalex Faspro (daratumumab and hyaluronidase-fihj) Indications

Treatment of adults with multiple myeloma (MM): in combination with bortezomib, melphalan, and prednisone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant (ASCT); in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory MM who have received ≥1 prior therapies; in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received ≥1 prior therapies; in combination with pomalidomide and dexamethasone in patients who have received ≥1 prior therapies including lenalidomide and a proteasome inhibitor (PI); as monotherapy after ≥3 previous lines of therapy, including a PI and an immunomodulatory agent, or in patients who are double-refractory to a PI and an immunomodulatory agent; in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment